Reviewing Diadexus (OTCMKTS:DDXS) & Nexalin Technology (NASDAQ:NXL)

Nexalin Technology (NASDAQ:NXL) and Diadexus (OTCMKTS:DDXS) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, analyst recommendations, risk, institutional ownership and dividends.

Earnings and Valuation

This table compares Nexalin Technology and Diadexus”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nexalin Technology	$300,000.00	26.56	-$8.22 million	($0.47)	-0.77
Diadexus	N/A	N/A	N/A	N/A	N/A

Diadexus has lower revenue, but higher earnings than Nexalin Technology.

Insider and Institutional Ownership

0.7% of Nexalin Technology shares are owned by institutional investors. 16.9% of Nexalin Technology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Nexalin Technology and Diadexus’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nexalin Technology	-3,018.12%	-191.88%	-166.43%
Diadexus	N/A	N/A	N/A

Analyst Ratings

This is a summary of recent ratings and price targets for Nexalin Technology and Diadexus, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nexalin Technology	1	0	0	0	1.00
Diadexus	0	0	0	0	0.00

Given Diadexus’ higher probable upside, analysts plainly believe Diadexus is more favorable than Nexalin Technology.

About Nexalin Technology

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas.

About Diadexus

Diadexus, Inc. engages in the research, development, and commercialization of pharmaceutical products. Its portfolio intends to treat cardiovascular diseases. The company was founded on November 27, 1995 and is headquartered in South San Francisco, CA.